The European neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). The key factors that primarily flourish the growth of the market include the rising geriatric population along with the rising prevalence of neurological disorders. As per the European Academy of Neurology 2019, around 60% of the population suffers from any one of the neurological disorders, and there is an increased burden of deaths and cases of neurological diseases.
To Request a Sample of our Report on European Neurological Disorder Drugs Market: https://www.omrglobal.com/request-sample/european-neurological-disorder-drugs-market
The European Academy of Neurology divided Europe into five major regions, which include, European Union (EU28), Western Europe, Central Europe, Eastern Europe, and WHO region Europe. The prevalence of neurological disorders in the EU28 is 307 million in which there were more than 1.1 million mortalities; the prevalence in Western Europe was 260 million with 0.8 million mortalities, and Central Europe has a prevalence of 67 million with 0.3 million mortalities.
While Eastern Europe with a prevalence of 130 million and 0.6 mortalities, while the WHO region Europe has a total prevalence of 542 million with more than 1.9 million mortalities. Such an increased prevalence of disorders among the people in the region is the primary factor creating scope for the European neurological disorder drugs industry growth over the forecast period.
Besides, the presence of the key players also supports the growth of the European neurological disorder drugs market. Players such as Novartis International AG, Allergan Plc., AstraZeneca Plc, and Boehringer Ingelheim International GmbH are significantly contributing to the market growth.
Market Coverage
· Market number available for – 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Disorder Type
· Region Covered- Europe
· Competitive Landscape- Novartis International AG, Allergan Plc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, and F. Hoffmann-La Roche Ltd.
Key questions addressed by the report
· What is the market growth rate?
· Which segment dominates the market in the base year?
· Which segment will project the fastest growth in the market?
· How COVID-19 impacted the market?
· Recovery Timeline
· Deviation from the pre-COVID-19 forecast
· Most affected segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report of European Neurological Disorder Drugs Market is Available at: https://www.omrglobal.com/industry-reports/european-neurological-disorder-drugs-market
Europe Neurological Disorder Drugs Market – Segmentation
By Disorder Type
· Epilepsy
· Alzheimer’s Disease
· Parkinson’s Disease
· Multiple Sclerosis
· Huntington Disease
· Others
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
